Journal Scans
Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients
Small PFS Advantage for High-Dose Imatinib in GIST
Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST)
20100101
2010 Feb 1
J Clin Oncol
Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients
J Clin Oncol. 2010 Feb 1; Epub ahead of print, Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST)
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Although the approved dose of imatinib for treating advanced gastrointestinal stromal tumor (GIST) is 400 mg/d, the highest feasible dose has been identified as 800 mg/d. Two large, randomized, phase III cooperative group studies using the same protocol─the European/Australian study (EU-AUS) and the United States/Canadian study (US-CDN)─were conducted to determine the best dose. Both studies randomized patients to standard-dose or high-dose imatinib, with crossover to the higher dose allowed. The...
